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Abstract
Background: India currently has the second largest burden of
infections due to COVID-19. Health Care Worker (HCW) shorta-
ges are endemic to Indian healthcare. It should therefore be a huge
priority to protect this precious resource as a critical component of
the systemic response to this pandemic. Advisories from the
Indian Council of Medical Research (ICMR) have focused on
using hydroxychloroquine prophylaxis against COVID-19 in at
risk HCW. This prophylaxis strategy has no evidence. In further
jeopardy there appear to insubstantial attempts to build this evi-
dence as well. In this connection, we commissioned a survey
within our Institution to estimate the penetration of hydroxy-
chloroquine (HCQ) use and use this to statistically model the
impact of current ongoing studies in India. We also briefly review
the literature on HCQ prophylaxis for COVID-19. 
Design and methods: A structured survey designed using
RedCAP application was disseminated among healthcare profes-
sionals employed at an academic referral tertiary care centre via
online social media platforms. The survey was kept open for the
entire month of June 2020. The survey was additionally used to
statistically model the size of studies required to comprehensively
address the efficacy of HCQ in this setting.
Results: 522 responses were received, of which 4 were incom-
plete. The ICMR strategy of 4 or more doses of HCQ was comple-
te only in 15% of HCW in our survey. The majority of respondents
were doctors (238, 46%). Amongst all category of responders,
only 12% (n=63) received the full course. A majority of those who
initiated the chemoprophylaxis with HCQ turned out to be medi-
cal professionals (59/63) with neither nurse nor other categories of
healthcare workers accessing the medication. The respondents of
our institutional survey did not report any life-threatening side
effects. Presuming efficacy as per ICMR modelling for new reg-
istry trial on the lines of the published case control study , equal
allocation between cases and controls and assuming a RR of 1.3.6,
the power of such a study would be very low for n=2000 for event
rates from 2.5-12.5%.  
Conclusion: We report the low penetration of HCQ chemo-
prophylaxis among the healthcare workers of our institution.  We
highlight the inherent drawbacks in the study design of current
national COVID related trial based on the statistical modelling of
our survey results and published literature, and thereby emphasis
the need of evidence-based strategies contributing to research
policy at national level.
Introduction
In December 2019, SARS-CoV-2 was identified as a cause of
fatal pneumonia in Wuhan, a city in the Hubei Province of China,
since then has rapidly spread and assumed pandemic proportions
within a few weeks. The sheer scale of the pandemic threatens
health systems.1,2 As the epidemiologic attributes of the disease
are being described more accurately (the size of at risk groups and
Article
Significance for public health
In the context of the mounting COVID pandemic in India crippling the public health system and curtailing healthcare workers of the country, we would like
to report the low hydroxychloroquine chemoprophylaxis rate from our institutional survey among healthcare workers that highlights the poor penetration of
a national hydroxychloroquine prophylaxis advisory. The brief review on hydroxychloroquine (HCQ) chemoprophylaxis strategy for COVID-19 that draws on
from existing literature and countrywide COVID trials reveals tenuous research designs which would be consequently informing public health policies of the
nation. We emphasize on the need for continued emphasis on evidence based protective measures and rigorous efforts to build this evidence when lacking.
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asymptomatic high infectivity) the prospects are not reassuring.3
A group of French researchers first described the beneficial
effect of hydroxychloroquine (HCQ) in the treatment of
COVID19.4 The paper has since been widely criticised for diffe-
rential treatment of control and intervention arms and not accoun-
ting for all patients in the combination treatment arm apart from its
miniscule size. Another paper from Korea has reported the use of
high dose HCQ as post exposure prophylaxis for healthcare
workers (HCW). This paper lacked a control arm altogether and
cannot provide any inference on the repurposing of HCQ as
prophylaxis against SARS CoV2 on account of its poor design.5
Likely based on this tenuous evidence the Indian Council of
Medical Research (ICMR) advocated HCQ for chemoprophylaxis
against SARS CoV-2 for at risk health workers in March 20206 and
has since expanded its use.7 The prevalence of this infection
amongst healthcare workers in India is unclear but ranges from 1-
5% in cross country survey based studies and could accelerate as
the country is on course to become the most affected nation global-
ly.8 HCQ has been the enfant terrible of this pandemic, right from
the first time it was repurposed to this day. Observational data has
negated benefits9-12 and has made a case for side effects (e.g., QT
interval prolongation) when used for the in hospital treatment of
COVID-19.13 HCQ has also been at the centre of controversies that
make strident claims for revisiting the whole process of peer
review for clinical research.14-16 More recently, a randomised con-
trolled trial has since shown that HCQ when used as post exposure
prophylaxis against SARS-CoV-2 is ineffective.17 Even as this lit-
erature evolves, the ICMR has since refashioned this advisory
extending use to HCW working in the non Covid areas of COVID-
19 hospitals and to non HCW categories such as police personnel
at risk of exposure.7 This advisory cites observational data
obtained prospectively as also a retrospective case control dataset.
The actual prospective data is not available for scrutiny. The retro-
spective case control study of HCQ use as chemoprophylaxis
against COVID-19 has been published in the Indian Journal of
Medical Research.18 This study, in our opinion, does not conclu-
sively show that HCQ is protective against SARS-CoV-2, and
therefore, cannot justify extended use as proposed. Outside India
there is now a call to restrict the use of HCQ to tightly monitored
environments such as clinical trials.19
Treatments and containment strategies for the pandemic, like
other disease conditions, must no less be based on solidity of evi-
dence. We point out the failure of the Indian healthcare research
apparatus in seeking conclusive evidence for its targeted response
to COVID-19 using the prophylactic use of HCQ against COVID-
19 as an example.
Design and Methods
An online structured questionnaire was developed and dissem-
inated using the REDCAPTM platform based on a cross sectional
survey study design. The questionnaire consisted of sociodemo-
graphic variables, co-morbidities, status of occupational exposure
to COVID positive patients, details of hydroxychloroquine admin-
istration and side effects and willingness to participate in COVID
related trials. Information on the survey was disseminated on the
hospital local area network, via electronic mails to all users, by
extensive use of the social medium of WhatsApp (FacebookTM )
and by word of mouth by nominated champions identified and
assigned to each clinical department. We established an institution-
al database and present here findings on the survey of HCQ pro-
phylaxis in our hospital.
The respondents of the survey were the healthcare staff work-
ing at the hospital irrespective of their status of interaction with
COVID positive patients. For dissemination, the survey proposals
were circulated amongst all cadres of healthcare workers viz.,
physicians, surgeons, nurses, paramedical staff and non-medical
workers involved in direct patient contact such as housekeeping
staff, as an online link to the survey hosted on RedCAP. Each of
these cadres was informed by team leaders and heads of depart-
ments including circulation by social media platforms like
WhatsApp and by word of mouth, following a snow ball sampling
technique. The survey was administered in English and participa-
tion was anonymous and voluntary. Non-medical staff lacking
felicity in English but willing to participate were provided help in
the form of transliterating questions to their mother tongue and fill-
ing the form on their behalf in their presence. The survey response
data was extracted from RedCAP platform in spreadsheet format to
facilitate formal analysis. 
Statistical analysis
Descriptive statistics was used to summarize baseline demo-
graphics and professional characteristics. Statistical power calcula-
tions based on the data from this survey and available published lit-
erature from India were also performed. All analysis was per-
formed on the SPSS version 17 (IBM, USA).
Results
Survey results
522 responses were received for the survey, of which 4 were
incomplete. The remaining results were analysed for utilisation of
prophylaxis, completeness of course of therapy, and, distribution
amongst the utilised by age, comorbid conditions and category of
healthcare workers. When reviewed, our limited survey depicted in
Figures 1-3 highlights low penetration of HCQ prophylaxis as a
sentinel finding. The ICMR strategy of deeming 4 or more doses
of HCQ17 to be protective was complete only in 15% of HCW in
our survey. The majority of respondents were doctors (238, 46%).
Amongst all category of responders, a mere 12% (n=63) received
the full course. 
A majority of those who initiated the chemoprophylaxis with
HCQ turned out to be medical professionals (59/63) with neither
nurse nor other categories of healthcare workers accessing the
medication. 85% of who had chosen to self-medicate per the advi-
sory turned out to be young medical professionals, presumably
healthy without comorbid conditions and resultant low risk for
severe COVID disease. A fair proportion of the medicated indivi-
duals (16%) had not however taken the loading dose. Only about
25% of those with comorbidities like systemic hypertension were
on HCQ. Most respondents on HCQ prophylaxis were willing to
take part in registry trials (70%) but would not want to change over
to a higher dose. Notably, our institutional data, the study from
ICMR17 and RCT15 do not reveal life threatening side effects11
and, efficacy apart, there seems to be no empirical basis to consider
electrocardiograms prior to and during HCQ administration, as
now advised recently.16 Our analysis shows that the penetration of
a national advisory on hydroxychloroquine prophylaxis was very
low (Figures 1-3) based on institutional data. Even smaller propor-
tions of those who consumed HCQ actually received what the
ICMR deems protective doses viz., 4 or more doses of HCQ.17
Also, unlike the figures from Italy (HCW infection rates of ~20%)
20only 5% of the HCW in the ICMR data suffered symptomatic and
confirmed SARS-CoV-2 infections.18,21 In their proposed model,









the use of HCQ increased the risk of COVID-19 initially [adjusted
odds ratio (AOR) 2.34, 95% CI: 1.23-4.83] before a superlative
protective effect afterwards for 4-5 doses (AOR 0.44, 95% CI:
0.22-0.88) and  for >6 doses (AOR 0.04, 95% CI: 0.01-0.16. An
OR=1.5 in the ICMR report corresponds to a relative risk (RR) of
1.3622 and an absolute risk reduction of 5.7%. Per our data and
their paper (Figures 1-3) the actual penetration of Covid prophy-
laxis now defined by a protective dose of >4-5 doses per their
study17 is only 10-20%. The actual infection rate amongst HCW is
also lower at 5%.17
Statistical modelling based on the survey 
The ICMR has now proposed a registry trial of 2000 HCW
across some centres in India (Supplementary data). We show
below how this study will likely be fruitless given the low event
rates overall and the low penetration of the measure.
Presuming efficacy as per ICMR modelling for new registry
trial on the lines of the published case control study,18 equal allo-
cation between cases and controls and assuming a RR of 1.3.6.
Figure 4 shows that the power of such a study would be very low
for n=2000 for event rates from 2.5-12.5%. This is a direct conse-
quence of the lower HCW infection rate reported in India com-
pared to the literature from countries like Italy.20 Now assuming
more realistic allocation drawing from our survey and the ICMR
paper,18 the allocation rate is closer to 12% as only about 12% of
HCW are on a supposedly effective regimen (>4 doses). Assuming
this allocation for n=2000, the effective treatment arm is 240. We
show (Figure 5) how large the sample size in the treatment group
would need to be to generate a study with a power of 90% as a
function of event rate for this skewed allocation. Thus, the pro-
posed registry trial is an exercise in futility.
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Figure 1. HCQ prophylaxis amongst healthcare workers by role :
intra-institutional survey report.
Figure 2. HCQ prophylaxis amongst healthcare workers by age:
intra-institutional survey report.
Figure 3. HCQ chemoprophylaxis distribution among patients
with co-morbidities: intra-institutional survey report.
Figure 4. Sample size modelling for different event rates assuming
equal allocation.
Figure 5. Sample size modelling for different event rates based on












Healthcare workers (HCW) have considerable risks of acquiring
the infection with risks described to be as high as 20% of the
workforce in Italy.20 India suffers a well described chronic neglect of
healthcare. With reference to the Indian workforce a recent seminal
paper suggests gross understaffing, disproportionate private health
representation and inadequate qualification as evident problems.23
With forecasts of high pandemic impact coupled to low healthcare
resource, a prescient prophylaxis strategy makes imminent sense,
when initiated early and if proven, efficacious.
Notably, India is the only country in the world to suggest a
workforce wide pharmacologic prevention as early as March 2020.6
A whole two months after the lockdown nailing 130 million Indians
to their homes, cases continue to surge and India is expected to face
a continuum of high clinical load24 from COVID-19 with simulta-
neous HCW attrition25 from the pandemic itself and measures such
as quarantine after workplace exposure. The state of Kerala in parti-
cular and India overall are currently in the throes of the crisis of
COVID-19 with explosive increases in numbers of cases, spiralling
test positivity rates and deaths even as there has been no attempt to
refashion this advisory or build evidence for its support at a systemic
level. 
The survey has indirectly contributed to the dissemination of
HCQ prophylaxis as a possible protective strategy against COVID-
19 amongst healthcare workers at our Institution. Despite extensive
dissemination using word of mouth, emails, social media and alerts
on the hospital Intranet actual responses received represented only
12-15% of total employees on the roll.  This is also an indirect
reminder of the grossly low penetration of the measure overall as it
is plausible that those who were motivated enough to take the medi-
cation would be more easily inclined to participate in an effort to
build evidence for a measure they have personally chosen. It is
uncertain as to what extent our survey is representative of the larger
practices in the state of Kerala or in India as a whole, limited as it is
to a single centre. The electronic nature of the survey may have also
limited acceptance amongst non-clinical healthcare workers such as
janitorial staff and others, no less at risk from workplace exposure.
A more representative registry such as that maintained by the
ICMR itself adverts to the dual difficulties of enumerating use based
on registry data (only about 60% of the intended sample could be
contacted for survey purposes) and about 30% of these respondents
had taken the deemed efficacious dose. This strengthens our statisti-
cal modelling and hypotheses on the size of studies actually required
to definitively address the efficacy or otherwise of this drug as
prophylaxis. It is uncertain whether the attack rate of HCW and
renewed motivation to attempt prophylaxis amongst HCW has been
altered in the backdrop of rapid increase in the numbers afflicted in
the period August- October 2020. In support of our contentions
however other investigators from India assuming an attack rate of
10% and a modest but pragmatic and reasonable absolute risk reduc-
tion of 2.5% attest to needing a sample size of over 6000 participants
to address the question of efficacy of HCQ as a prophylactic measu-
re.26 It is however surprising that the trialists here continue to adopt
the dosing scheme of the ICMR which has no evidentiary basis
whatsoever and is clearly considered to deliver suboptimal doses.
Simulation from the University of Minnesota27 used to drive the
RCT reported in the New England Journal of Medicine from
Minnesota17 and other centres in North America is the only available
pharmacologic basis to provide a trial prescription for appropriate
testing. If safety is a purported concern as Table 1 shows the RCT
has demonstrated safety at far higher doses than the ICMR prescrip-
tion with some of the participants delivered drug at distant locations
and without electrocardiographic monitoring, a concern since raised
about widespread unsupervised use of this molecule28. Further, the
trial now proposes to commence largely in the private sector in India
which has not been in the foreground of COVID-19 healthcare per
scale. We surmise, based on our research experience that the propo-
sed enrolment target will be difficult to achieve within a reasonable
time given the acceleration of the pandemic making extrapolation
post conclusion of limited utility. The private healthcare system also
lacks organised, well-regulated research networks on the proposed
scale of this trial. A single dose of HCQ has a plasma peak in 3.26
hours with a pharmacokinetic half-life of 2963 hours. Its main
metabolite desethyl HCQ has a half-life of 40-50 days.29 It follows
that given these kinetics it might prove difficult to enrol a rigorous
placebo group given that the ICMR strategy has predated this trial
by several months. The ICMR strategy could well have been adop-
ted to a great degree in the public healthcare system which has been
in the forefront of COVID-19 care in India and where the research
body has huge advocacy.
Summative data from several quantitative reviews30,31 purports
to the near complete lack of evidence supporting efficacy of HCQ
prophylaxis overall. These reviews point to the overall lack of evi-
dence. It is therefore logical to ask as to whether or not HCQ imparts
protection beyond that offered by standard measures such as use of
personal protective equipment (PPE). The overall design of the
HOPE trial26 is therefore compelling as it seeks to evaluate compar-
ative efficacy of a standard protective measure such as use of per-
sonal protective equipment (PPE) alone measured against use of
PPE with HCQ as an adjunct. 
In practice, however it is still contentious to define what consti-
tutes adequate personal protective equipment and which of the con-
stituents are more critical to protection vs others. Exposures are also
not standard in the face of the pandemic with aerosol generating pro-
cedures putatively of higher risk. Shortage of critical supplies such
as PPE were reported in the initial stages of the pandemic but it is
well known that even now certain components of the PPE arsenal
such as N95 masks continue to be reprocessed: the diversity of
reprocessing procedures and the lack of universal guidance from
infection control bodies such as the Infectious Disease Society of
America32 also threaten to imperil standardisation of PPE as a study
intervention, particularly in multicentric endeavours. The ICMR
registry study has delineated some of these problems but has shied
away from proposing a rigorous research design that incorporates
these questions. The HOPE trial from India also leaves defining
components of a PPE to institutional practice and this is likely to
negatively impact study rigor. While some of these factors are diffi-
cult to control for in the situation of a pandemic standardisation in
terms of defining components of a multicomponent intervention
such as PPE seems a reasonable demand for trialists to seek evi-
dence for a critical component of COVID-19 response- healthcare
worker protection from this biohazard.
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Table 1. HCQ dosing for prophylaxis against COVID-19: dosing
schemes ICMR6,17 vs Boulware.15
Day of therapy                             ICMR                   Minnesota
1                                                                    800 mg                             1400 mg
2                                                                    400 mg                              600 mg
3                                                                         -                                    600 mg
4                                                                         -                                    600 mg
5                                                                         -                                    600 mg
End of week 1                                           1200 mg                            3800 mg
Week 2 onwards                        400 mg for three weeks                    -
Total dose of HCQ                                   2400 mg                            3800 mg











Our study demonstrates the poor penetration of the national
advisory based HCQ prophylaxis among healthcare workers of our
institution. We illustrate the poor research response of our country
to the pandemic of COVID-19 using the advocacy of hydroxych-
loroquine prophylaxis against COVID-19 by the Indian Council of
Medical Research as an example. We show how this research body
(which has a stranglehold on research funding in the public health
system) refuses to adapt to its own published observations, the
evolving medical literature outside India and has not led Indian
medical research from the front. In a resource limited system, con-
tinued loss of healthcare workers is ethically reprehensible both
from the perspective of personnel lost and the health delivery
apparatus as a whole. Apathy to such a critical component of
COVID-19 care is emblematic of India’s poor emphasis on public
health and its instruments of delivery. While the private system has
attempted to move beyond just care delivery to fostering clinical
research its efforts can, in no substantial measure contribute to
research policy at the national level given its lack of a networked
collaborative research apparatus. The pandemic and this illustrati-
ve story should serve as a clarion wake up call to all those who
serve and care for the health of the Indian people, in themselves, a
substantial part of the human population on earth today. 
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